Verve Therapeutics (NASDAQ:VERV) Receives Market Perform Rating from William Blair

William Blair reiterated their market perform rating on shares of Verve Therapeutics (NASDAQ:VERV) in a report released on Tuesday morning,Benzinga reports.

VERV has been the topic of several other reports. Wall Street Zen raised shares of Verve Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. HC Wainwright lifted their price target on shares of Verve Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, April 14th. Guggenheim increased their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, April 15th. Cantor Fitzgerald raised shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 15th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $13.00 price target (down previously from $39.00) on shares of Verve Therapeutics in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.25.

Verve Therapeutics Stock Performance

Shares of VERV opened at $11.38 on Tuesday. The business’s 50-day moving average is $5.02 and its two-hundred day moving average is $5.84. The company has a market capitalization of $1.01 billion, a P/E ratio of -5.39 and a beta of 1.67. Verve Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $11.41.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.36. The company had revenue of $32.98 million during the quarter, compared to analysts’ expectations of $7.13 million. Verve Therapeutics had a negative return on equity of 35.81% and a negative net margin of 303.64%. Analysts forecast that Verve Therapeutics will post -2.49 EPS for the current year.

Hedge Funds Weigh In On Verve Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its position in shares of Verve Therapeutics by 1.9% during the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock valued at $627,000 after buying an additional 2,093 shares during the period. IFP Advisors Inc lifted its stake in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after purchasing an additional 8,237 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Verve Therapeutics by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 220,502 shares of the company’s stock worth $1,244,000 after purchasing an additional 5,262 shares during the period. US Bancorp DE raised its holdings in Verve Therapeutics by 62.8% in the 4th quarter. US Bancorp DE now owns 30,616 shares of the company’s stock valued at $173,000 after buying an additional 11,810 shares during the period. Finally, Arizona State Retirement System lifted its position in Verve Therapeutics by 15.8% in the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company’s stock valued at $111,000 after buying an additional 2,669 shares during the last quarter. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.